Replicel
Collapse
X
-
-
Comment
-
The placebo groups recieved injections. The wounding process incurred from the injection may be responsible for some the results seen in the placebo group.Comment
-
Oh wait, they don't gain additional equity from the secondary market AND they've already secured their funding for phase 2 through private investors BEFORE the "pump".
Please stop talking if you don't have anything useful to contribute.Comment
-
-
12% increase in vellus hair.seemingly bad but hope it will compund in 12 and 24 months follow ups.Comment
-
i think you're right. cotsarelis and others could show this effect at least in mice. but could also be just the normal result after six month of any dormant, resting, circulating hairs in the skin. but the same for the real treatment site.Comment
-
I'm not too clear on the study design, so I'm hoping you'll bear with me and someone can explain. From the press release it sounds like they counted actual hairs on the participants' heads. Obviously hair grows in cycles, and the mere irritation from the placebo injection could have resulted in new growth. I use ketoconazole shampoo for this same purpose. Are they not looking at the actual hair follicle, so see whether existing ones have been plumped up as a result of the treatment, or whether ones that weren't even visible before can now be seen? Thanks for any clarification. I would like to understand all this better.Comment
-
TrichoScan is promoted as a validated and precise tool for measurement of hair growth parameters. Under certain conditions, it may seem suitable for clinical trials evaluating treatment response. We provide evidence that this is an overstatement. This study concludes that TrichoScan-analyzed anagen/ …Comment
-
It's really tough not to get down about these results. Unless there is a dramatic increase in results from 6-12 months (which i'm not ruling out as a possibility, though I think unlikely to see anything major), i can't see how they could justify investing the cash necessary to push this forward. My guess is that they need to get the terminal hair count over the 20% mark to have anything that would warrant further pursuit. They are very, very far from that. So, it would take a turnaround of epic proportions to get them back in line with what David Hall was saying in the interviews. I'm not holding out any hope for that.
If the results stay as they are, even if they double what they have, Replicel is finished. They're going to have a hard time attracting investor money with those numbers. And I think that attracting a big corporate buyer is very unlikely. Or if it does happen, it's gonna be at a price that makes David Hall cry. So, depending on the next interim results (12 months) this turkey might be cooked. I'll say it doesn't look good at all.Comment
-
Comment
-
Comment
-
Since the primary purpose of this clinical trial is safety, I wonder if Replicel chose the temple region for injection because they had some reason to believe that was where any negative health effects would be most apparent?Comment
Comment